COCRYSTAL PHARMA, INC.: operating lease liability

What this measure means

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Exact concept: us-gaap:OperatingLeaseLiability. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• COCRYSTAL PHARMA, INC.: total assets
• COCRYSTAL PHARMA, INC.: total liabilities
• COCRYSTAL PHARMA, INC.: stockholders equity
• COCRYSTAL PHARMA, INC.: cash and cash equivalents
• COCRYSTAL PHARMA, INC.: net income or loss
• COCRYSTAL PHARMA, INC.: operating cash flow
• COCRYSTAL PHARMA, INC.: capital expenditure payments
• COCRYSTAL PHARMA, INC.: financing cash flow
• COCRYSTAL PHARMA, INC.: investing cash flow
• COCRYSTAL PHARMA, INC.: retained earnings or deficit
• COCRYSTAL PHARMA, INC.: basic weighted-average shares
• COCRYSTAL PHARMA, INC.: diluted weighted-average shares
• COCRYSTAL PHARMA, INC.: basic earnings per share
• COCRYSTAL PHARMA, INC.: diluted earnings per share
• COCRYSTAL PHARMA, INC.: income tax expense or benefit
• COCRYSTAL PHARMA, INC.: net property, plant and equipment
• COCRYSTAL PHARMA, INC.: share-based compensation expense
• COCRYSTAL PHARMA, INC.: operating income or loss
• COCRYSTAL PHARMA, INC.: current assets
• COCRYSTAL PHARMA, INC.: interest expense
• COCRYSTAL PHARMA, INC.: current liabilities
• COCRYSTAL PHARMA, INC.: current accounts payable
• COCRYSTAL PHARMA, INC.: goodwill carrying amount
• COCRYSTAL PHARMA, INC.: net current accounts receivable
• COCRYSTAL PHARMA, INC.: operating expenses
• COCRYSTAL PHARMA, INC.: net inventory
• COCRYSTAL PHARMA, INC.: gross profit
• COCRYSTAL PHARMA, INC.: research and development expense
• COCRYSTAL PHARMA, INC.: common shares outstanding
• COCRYSTAL PHARMA, INC.: cash including restricted cash
• COCRYSTAL PHARMA, INC.: additional paid-in capital
• COCRYSTAL PHARMA, INC.: operating lease right-of-use asset
• COCRYSTAL PHARMA, INC.: gross property, plant and equipment
• COCRYSTAL PHARMA, INC.: accumulated depreciation on property, plant and equipment
• COCRYSTAL PHARMA, INC.: accrued current liabilities
• COCRYSTAL PHARMA, INC.: prepaid expenses and other current assets
• COCRYSTAL PHARMA, INC.: net deferred tax assets
• COCRYSTAL PHARMA, INC.: comprehensive income or loss
• COCRYSTAL PHARMA, INC.: net income available to common stockholders
• COCRYSTAL PHARMA, INC.: general and administrative expense
• COCRYSTAL PHARMA, INC.: depreciation expense
• COCRYSTAL PHARMA, INC.: nonoperating interest expense
• COCRYSTAL PHARMA, INC.: other nonoperating income or expense
• COCRYSTAL PHARMA, INC.: nonoperating income or expense
• COCRYSTAL PHARMA, INC.: current income tax expense or benefit
• COCRYSTAL PHARMA, INC.: deferred income tax expense or benefit
• COCRYSTAL PHARMA, INC.: interest paid, net
• COCRYSTAL PHARMA, INC.: proceeds from issuing common stock
• COCRYSTAL PHARMA, INC.: operating lease payments
• COCRYSTAL PHARMA, INC.: change in accounts receivable
• COCRYSTAL PHARMA, INC.: change in inventories
• COCRYSTAL PHARMA, INC.: change in accounts payable

Inspect the source

Entity

COCRYSTAL PHARMA, INC. / CIK 0001412486

Captured

2026-09-20T08:02:05.848Z

SEC response SHA-256

4ddb37c0fdc725320702a24acde07528776450e5d3542ebbf59be5aa264a757e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001412486.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))